Cardiovalve is a pioneer in the field of transcatheter valve replacement. The company has been part of Venus Medtech (HKG:2500) since 2022. We help patients suffering from heart valve disease to access innovative solutions. Our products empower physicians to offer their patients an improved quality of life without the need for open-heart surgery. We build our solutions from the bottom up for transfemoral/transseptal delivery, accessing the heart through the femoral vein. This unique approach offers significant benefits, including a short implant profile (mimics a surgical-like design), and minimal protrusion to the left ventricle, minimizing interference in the cardiac blood flow and increasing safety. Cardiovalve's objective is to seek approvals in the EU, China, and North America for its system after final proof of the safety and performance of its system in clinical studies. Learn more about Cardiovalve at www.cardiovalve.com.